Endurant Capital Management LP Apellis Pharmaceuticals, Inc. Transaction History

Endurant Capital Management LP

  • $0
  • Q1 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 15, 2020
SELL
$17.91 - $44.33 $346,773 - $858,317
-19,362 Closed
0 $0
Q4 2019

Feb 14, 2020
SELL
$22.1 - $30.8 $64,509 - $89,905
-2,919 Reduced 13.1%
19,362 $593,000
Q3 2019

Nov 14, 2019
BUY
$24.09 - $32.18 $536,749 - $717,002
22,281 New
22,281 $537,000
Q1 2018

May 15, 2018
SELL
$14.01 - $26.02 $246,576 - $457,952
-17,600 Closed
0 $0
Q4 2017

Feb 14, 2018
BUY
$12.71 - $21.7 $223,696 - $381,920
17,600
17,600 $382,000

Others Institutions Holding APLS

# of Institutions
337
Shares Held
111M
Call Options Held
1.26M
Put Options Held
1.14M
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.98B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Endurant Capital Management LP Portfolio

Follow Endurant Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Endurant Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email